Johnson & Johnson extends contract with Trellus Health for IBD platform
#Johnson & Johnson #Trellus Health #IBD #inflammatory bowel disease #digital health platform #contract extension #patient engagement #health innovation
📌 Key Takeaways
- Johnson & Johnson (J&J) and Trellus Health have renewed their partnership for the IBD digital care platform.
- The extension was publicly announced by J&J in 2024 from its global headquarters.
- The agreement expands patient engagement tools to support individuals with inflammatory bowel disease.
- The collaboration is part of J&J’s broader strategy to integrate digital health solutions into its therapeutic portfolio.
- The renewed contract is expected to drive improved health outcomes and accelerate the development of new digital care technologies.
📖 Full Retelling
Johnson & Johnson and Israeli digital‑health firm Trellus Health announced that the U.S. pharmaceutical giant has extended its contract for the IBD (inflammatory bowel disease) platform. The partnership, disclosed from J&J’s global headquarters, was announced in 2024 as part of the company’s ongoing strategy to expand digital health solutions for patients with chronic conditions. The extension aims to broaden patient engagement, improve disease management outcomes and strengthen the joint innovation pipeline between the two firms.
🏷️ Themes
Digital health, IBD management, Strategic partnership, Patient engagement, Innovation in therapeutic platforms
Entity Intersection Graph
No entity connections available yet for this article.